Enliven Therapeutics, Inc. (ELVN)
NASDAQ · Manufacturing · Pharmaceutical preparations
$44.75−$0.4200 (−0.93%) on the dayAs of the close; data may be delayed.
ELVN price, last 12 months
Key stats
- Previous close
- $45.17
- Open
- $45.54
- Day range
- $44.18 – $45.77
- 52-week range
- $14.79 – $62.32
- Volume
- 963.8K
- Avg volume (20 days)
- 1.4M
- Market cap
- $3.3B
Performance
1W−9.5%
1M−26.5%
3M−10.6%
6M+13.9%
YTD+190.6%
1Y+133.1%
vs S&P 500, 1Y+116.3 pts
Technicals and fundamentals
About Enliven Therapeutics, Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $3.3B